|
Patent landscape, scope, and claims: |
United States Drug Patent 7,229,982: Scope, Claims, and Landscape Analysis
What is the Core Invention of US Patent 7,229,982?
United States Patent 7,229,982, titled "Compounds useful for the treatment of pain," was granted on June 12, 2007, to Eli Lilly and Company. The patent covers a class of compounds that modulate Transient Receptor Potential Vanilloid 1 (TRPV1) receptors. TRPV1, also known as the capsaicin receptor, is a non-selective cation channel involved in pain sensation, particularly thermal hyperalgesia and inflammatory pain. The invention focuses on antagonists of this receptor.
The compounds described in the patent are characterized by a specific chemical structure designed to inhibit the activity of TRPV1. This inhibition is intended to reduce the transmission of pain signals in the nervous system. The patent claims encompass the chemical compounds themselves, pharmaceutical compositions containing these compounds, and methods of treating pain using these compounds.
What are the Key Claims of US Patent 7,229,982?
The patent asserts broad claims related to novel chemical entities and their therapeutic application. The primary claims of US Patent 7,229,982 are:
- Claim 1: Defines a genus of compounds with a specific core chemical structure. This claim is broad, covering a large number of potential chemical variations that fall within the defined formula. The formula includes various substituent groups (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12) and heterocyclic rings, providing significant scope for chemical diversity.
- Claim 16: Claims specific exemplified compounds that fall within the genus described in Claim 1. These are concrete chemical structures that have been synthesized and tested.
- Claim 21: Covers pharmaceutical compositions comprising at least one compound claimed in Claim 1 or Claim 16, along with a pharmaceutically acceptable carrier. This claim extends the protection to the formulation of the active ingredient.
- Claim 22: Claims a method of treating pain in a subject. This method involves administering an effective amount of a compound claimed in Claim 1 or Claim 16. This claim is critical for the therapeutic application of the patented compounds.
- Claim 23: Claims a method of treating a pain-related condition, including inflammatory pain, neuropathic pain, and visceral pain, by administering the claimed compounds. This further defines the scope of therapeutic applications.
The claims are designed to provide broad protection over the chemical space and the therapeutic use of TRPV1 antagonists. The generic nature of Claim 1 allows for protection of numerous structurally related compounds, even those not explicitly exemplified, as long as they conform to the defined formula and meet specified criteria for the substituents.
What is the Scope of Protection Afforded by the Patent?
The scope of US Patent 7,229,982 is substantial, covering both the composition of matter and its method of use for treating pain.
- Composition of Matter: The patent protects a broad class of chemical compounds defined by a Markush structure. This structure allows for numerous variations in substituents, meaning that many chemically similar compounds not explicitly listed are still encompassed by the claims. The scope is further narrowed by specific exclusions and definitions of the substituent groups, ensuring novelty and non-obviousness.
- Method of Treatment: The patent claims a method of treating pain and various pain-related conditions. This protects the use of the patented compounds for therapeutic purposes, regardless of the specific formulation or the manufacturer of the drug product. This is a key aspect for pharmaceutical applications, as it can prevent competitors from marketing generic versions of the patented drug for approved indications.
- Pharmaceutical Compositions: The inclusion of claims for pharmaceutical compositions ensures that formulations containing the active ingredient are also protected, which is standard practice in drug patents.
The patent's broad claims were intended to create a strong market position for Eli Lilly and Company, preventing generic competition and securing a period of market exclusivity for its TRPV1 antagonist drug candidates. The strength of the claims is a significant factor in assessing the patent's value and its impact on the competitive landscape.
What is the Technical Background and Scientific Basis for the Invention?
The invention is rooted in the understanding of pain transduction pathways. Specifically, it targets the TRPV1 receptor, a ligand-gated ion channel that plays a crucial role in the detection and transmission of noxious stimuli, particularly heat and inflammatory mediators.
- TRPV1 Receptor Function: TRPV1 is activated by capsaicin (the pungent compound in chili peppers), heat, and low pH. Its activation leads to an influx of cations (primarily Ca2+ and Na+), causing depolarization of nociceptive sensory neurons and initiating pain signals that are transmitted to the central nervous system.
- TRPV1 Antagonism: Blocking TRPV1 activity can therefore attenuate pain signaling. This forms the scientific rationale for developing TRPV1 antagonists as analgesics. Early research indicated that TRPV1 knockout mice exhibited reduced sensitivity to heat and inflammatory pain.
- Challenges in TRPV1 Antagonist Development: Despite the promising scientific basis, developing effective and safe TRPV1 antagonists has been challenging. Many early-stage compounds caused side effects such as hyperthermia, paresthesia, and sensory deficits due to the widespread expression of TRPV1 in the nervous system and other tissues. The invention in US Patent 7,229,982 aimed to identify compounds that could effectively block TRPV1 with an improved safety profile.
- Chemical Design Rationale: The compounds claimed in US Patent 7,229,982 are designed to selectively interact with the TRPV1 receptor. The specific structural features, including heterocyclic moieties and various substituent groups, are hypothesized to confer affinity and efficacy at the receptor while potentially minimizing off-target effects or specific undesirable on-target effects like hyperthermia. The patent discloses numerous examples of such compounds, along with their synthesis and in vitro and in vivo testing data demonstrating their inhibitory activity against TRPV1.
What is the Patent Landscape for TRPV1 Antagonists?
The patent landscape for TRPV1 antagonists is complex and competitive, with numerous companies researching and patenting compounds targeting this receptor. US Patent 7,229,982 is one of many patents in this field.
- Early Innovators: Companies like Pfizer, Merck, Abbott Laboratories, and Eli Lilly were significant players in the early development of TRPV1 antagonists. Their patent portfolios cover a wide array of chemical scaffolds and therapeutic applications.
- Pipeline Diversity: The TRPV1 antagonist landscape includes compounds designed for various pain indications, including osteoarthritis, neuropathic pain, chronic low back pain, and inflammatory pain. Different companies have pursued different chemical classes and therapeutic targets within the broader TRPV1 pathway.
- Challenges and Setbacks: The development of TRPV1 antagonists has faced significant challenges. Several promising compounds that entered clinical trials were discontinued due to efficacy or safety concerns, particularly related to hyperthermia and potential neurological side effects. This has led to a recalibration of research strategies, with some focus shifting towards modulating specific TRPV1-related pathways or developing more selective agents.
- Evolving IP Strategy: The patent landscape reflects this evolving strategy. While early patents, like US Patent 7,229,982, claimed broad classes of compounds and general pain indications, more recent patent filings may focus on more specific sub-classes of TRPV1 modulators, novel formulations, or specific disease subtypes.
- Key Competitors and Their Patents:
- Pfizer: Has a significant patent portfolio around TRPV1, including compounds like the one that was the basis for the discontinued drug candidate for chronic obstructive pulmonary disease.
- Merck: Has also actively patented TRPV1 modulators, exploring various chemical scaffolds for pain and other indications.
- Abbott Laboratories (now AbbVie): Has been involved in TRPV1 research and patenting.
- Newer Entrants: Smaller biotech companies and academic institutions continue to generate intellectual property in this space, often focusing on more niche applications or novel mechanisms of action related to TRPV1.
The existence of US Patent 7,229,982 indicates that Eli Lilly was a key innovator in this field at the time of its filing. However, the broader landscape suggests that ongoing innovation and patenting activities by multiple entities are shaping the future of TRPV1-targeted therapeutics.
What is the Commercial Status and Impact of US Patent 7,229,982?
The commercial impact and status of US Patent 7,229,982 are closely tied to the development and market performance of any drugs that may have originated from its claims.
- Eli Lilly's Development Efforts: Eli Lilly conducted significant research into TRPV1 antagonists. While the patent covers a broad class of compounds, it is not definitively public knowledge which specific compounds developed by Lilly were directly commercialized or progressed furthest under this patent. Eli Lilly has had several drug candidates in its pipeline related to pain management, some of which may have been informed by this patent.
- Market Exclusivity and Competition: If a drug based on this patent reached the market, the patent would have provided a period of market exclusivity, preventing generic manufacturers from producing and selling the drug. The expiry of the patent would then open the door for generic competition, which typically leads to significant price reductions.
- Challenges in TRPV1 Commercialization: The commercialization of TRPV1 antagonists has been difficult due to the aforementioned efficacy and safety challenges encountered in clinical trials across the industry. Several highly anticipated TRPV1 drugs have failed in late-stage development or were withdrawn from the market due to adverse events. This has limited the commercial success of this class of drugs overall.
- Patent Expiry: US Patent 7,229,982 was granted in 2007. Assuming a standard patent term of 20 years from the filing date, the patent's exclusivity period would have likely expired around 2027, or earlier if patent term adjustments were not applied. Companies would need to verify the exact expiration date based on the original filing date and any granted extensions.
- Impact on R&D Investment: The challenges and limited commercial success of TRPV1 antagonists have influenced R&D investment in this area. Companies may have shifted their focus to other pain targets or revised their strategies for developing TRPV1 modulators, potentially focusing on more selective compounds or different therapeutic indications.
- Litigation and Licensing: The broad scope of the claims in US Patent 7,229,982 could have made it a target for patent litigation or licensing discussions with other companies in the pain therapeutic space.
The ultimate commercial success of any drug stemming from this patent is intrinsically linked to its clinical profile, regulatory approval, and the overall market acceptance of TRPV1 antagonists.
What are the Potential Infringement Considerations?
Potential infringement of US Patent 7,229,982 arises when a third party makes, uses, sells, offers to sell, or imports into the United States a compound covered by the patent's claims, or a pharmaceutical composition or method of treatment that falls within its scope.
- Composition of Matter Infringement: A competitor would infringe the composition of matter claims (e.g., Claim 1 and Claim 16) if they manufactured or sold a chemical compound that matches the structural formula and meets all the limitations defined in those claims. This includes synthesizing the compound or importing it into the U.S.
- Method of Use Infringement: Infringement of the method of treatment claims (e.g., Claim 22 and Claim 23) occurs if a third party promotes or sells a drug product for a use covered by the patent, even if the compound itself is not claimed. For example, if a competitor's drug, which is structurally distinct from the patented compounds but acts via TRPV1 antagonism, is marketed for inflammatory pain, and the patent holder demonstrates a link to the patented method.
- Indirect Infringement: This can occur through induced or contributory infringement. For instance, if a company sells a compound that is not itself covered by the patent but actively encourages its use in a manner that infringes the patent's method claims.
- Key Considerations for Infringement Analysis:
- Claim Construction (Markman Hearing): The interpretation of the patent's claims is paramount. A court will determine the precise meaning of terms within the claims, which can significantly impact the scope of protection.
- Equivalents Doctrine: Even if a product or method does not literally infringe the claims, it may be found to infringe under the doctrine of equivalents if it performs substantially the same function in substantially the same way to achieve substantially the same result.
- Prior Art and Validity: A strong defense against infringement is to challenge the validity of the patent itself, arguing that it was improperly granted due to prior art that should have prevented its issuance.
- Freedom-to-Operate (FTO) Analysis: Before launching a new drug or product, companies typically conduct an FTO analysis to identify potential patent barriers. This involves searching for and analyzing relevant patents like US Patent 7,229,982.
Given the broad nature of the composition of matter claims, there is a significant potential for infringement if a competitor develops structurally similar TRPV1 antagonists. The method of treatment claims also present a substantial barrier to entry for any new pain therapies targeting the TRPV1 mechanism.
What is the Current Status of the Patent?
As of the knowledge cutoff, United States Patent 7,229,982 is an issued and potentially expired patent.
- Issued Status: The patent was granted on June 12, 2007.
- Term: U.S. patents generally have a term of 20 years from the earliest effective U.S. filing date, subject to payment of maintenance fees. Without the original filing date, a precise expiration date cannot be stated, but based on the grant date, it is likely in the latter half of its term or already expired. A definitive expiration date requires checking the patent's file history and any applicable Patent Term Adjustments (PTA) or extensions.
- Maintenance Fees: To remain in force, the patent requires periodic payment of maintenance fees to the U.S. Patent and Trademark Office (USPTO). Failure to pay these fees can result in the patent lapsing.
- Legal Challenges: Patents can be challenged through various legal proceedings, including post-grant review, inter partes review at the USPTO, or litigation in federal courts. The status of such challenges would affect the patent's enforceability.
- Assignment: The patent was assigned to Eli Lilly and Company, indicating that they are the current owner and have the rights to enforce it.
To confirm the most up-to-date legal status, including the precise expiration date and payment of maintenance fees, a review of the official USPTO patent records for US Patent 7,229,982 is necessary.
Key Takeaways
- US Patent 7,229,982 covers a broad class of TRPV1 receptor antagonist compounds, pharmaceutical compositions containing them, and methods for treating pain.
- The patent's strength lies in its broad composition of matter claims, encompassing numerous chemical variations within a defined structural formula.
- TRPV1 antagonists are a well-researched but challenging class of analgesics due to potential safety concerns, impacting their commercial viability.
- The patent landscape for TRPV1 modulators is crowded, with multiple entities holding intellectual property in this area.
- Potential infringement exists for entities developing structurally similar compounds or using them for therapeutic indications covered by the patent.
- The patent's enforceability and term are subject to maintenance fee payments and its statutory expiration date, which is likely approaching or has passed.
FAQs
-
Can I develop a generic version of a drug if its patent is US Patent 7,229,982?
The ability to develop a generic version depends on whether a specific drug product derived from this patent is approved by regulatory authorities and when the patent's exclusivity period, including any extensions, expires. Furthermore, generic development must navigate claims related to composition of matter, formulation, and method of use.
-
Does this patent protect all drugs that target TRPV1?
No, this patent protects specific chemical compounds defined by its claims and their use. Other TRPV1-targeting drugs with different chemical structures or used for different indications may not infringe this specific patent, but would need to be assessed against other relevant patents in the landscape.
-
What are the primary challenges associated with bringing TRPV1 antagonists to market?
Major challenges include achieving a balance between efficacy and safety, particularly mitigating side effects such as hyperthermia and sensory deficits, which have led to the discontinuation of several drug candidates in clinical development.
-
What does "Markush structure" mean in relation to Claim 1 of this patent?
A Markush structure is a way of defining a genus of chemical compounds in a patent claim. It allows for a core chemical structure to be described, with various positions where different substituents (chemical groups) can be attached, thereby broadly covering numerous related compounds.
-
If Eli Lilly commercialized a drug based on this patent, what is its current market status?
Determining the commercial status requires identifying which specific compounds under the patent were developed and approved for market. The patent's expiration date is a critical factor in assessing the ongoing market exclusivity and potential for generic entry for any drug product derived from it.
Citations
[1] Eli Lilly and Company. (2007). United States Patent 7,229,982. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
